另外，多家创新药龙头确认盈利拐点。恒瑞医药2025年创新药收入占比近六成，指引2026年增长超30%；诺诚健 华、云顶新耀、晶泰控股等药企也在2025年实现扭亏为盈。 还值得注意的是，2026年政府工作报告将生物医药的战略地位显著提升，首次将其与集成电路、航空航天并列， 明确为国家新兴支柱产业。 | 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | 最新 | | --- | --- | --- | --- | --- | --- | --- | | 688710 | 益諾思 | | 12.15 | 91.07亿 | 46.32 | 64.60 | | 688799 | 华纳药厂 | | 11.70 | 71.96亿 | 14.88 | 54.80 | | 300204 | 舒泰神 | | 11.41 | 123亿 | -5.67 | 25.77 | | 002082 | 万邦德 | + | 10.01 | 159亿 | 86.93 | 26.04 | | 600513 | 联环药业 | 1 | 10.01 | 73.11亿 | 39.87 | 25.61 | | 603127 | 昭衍新 ...

Each week we run a DCF (Discounted Cash Flow) model on a company from our watchlist.This week’s pick: Pfizer Inc. (PFE).ProfilePfizer is one of the world’s largest pharmaceutical companies, focused on developing and commercializing medicines and vaccines across oncology, immunology, cardiology, and infectious diseases.The company gained global prominence during the COVID-19 pandemic through its vaccine and antiviral treatments, which temporarily drove exceptional revenue and cash flow. However, Pfizer has s ...

Companies Novo Nordisk A/S Reporting by Carlos Méndez in Mexico City; Editing by Rashmi Aich Our Standards: The Thomson Reuters Trust Principles., opens new tab US FDA approves Novo's insulin injection for type 2 diabetes | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv The logo of Danish drugmaker Novo Nordisk, Copenhagen, Denmark, September 26, 2023. REUTERS/Tom Little REFILE - CORRECTING LOCATION Purchase Licensing Rights, opens new tab Follow March ...

Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDAAwiqli® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing these injections from seven to one per weekNovo Nordisk expects to launch Awiqli® nationwide in the US in the second half of 2026. Bagsværd, Denmark, 27 March 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL ...

New York, New York--(Newsfile Corp. - March 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.SO WHAT: If you purchased Inovio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held Tuesday, March 24, 2026. A total of 2,407,148 common shares of the Company were represented at the Meeting, representing a ...

Alpha Cognition (NasdaqCM:ACOG) Q4 2025 Earnings call March 26, 2026 04:30 PM ET Company ParticipantsDave Storms - Director of Equity ResearchHenry Du - Interim CFOLauren D'Angelo - COOMichael McFadden - CEOConference Call ParticipantsRam Selvaraju - Managing Director and Senior Healthcare AnalystOperatorGreetings. Welcome to Alpha Cognition fourth quarter and full year 2025 earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presenta ...

Journey Medical Corporation (DERM) reported $16.08 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 18.1%. EPS of -$0.04 for the same period compares to $0.08 a year ago.The reported revenue represents a surprise of -15.68% over the Zacks Consensus Estimate of $19.07 million. With the consensus EPS estimate being -$0.06, the EPS surprise was +27.27%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how the ...

Alpha Cognition (NasdaqCM:ACOG) Q4 2025 Earnings call March 26, 2026 04:30 PM ET Speaker4Greetings. Welcome to Alpha Cognition fourth quarter and full year 2025 earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to Henry Du ...

PresentationLars Sorensen Good afternoon, everybody. On behalf of the Board, a warm welcome to Novo Nordisk Annual General Meeting of 2026. I'm Lars Rebien Sorensen. I'm the Chair of the Board, and it's my pleasure to welcome you to this Annual General Meeting. For those of you who prefer Danish over English, real-time translation is available here at the Bella center. For those of you that participate online, you can choose the preferred language in the broadcast system. '25 was a profound year of transfor ...